In summary, PD-L1 dominates over PD-1, whereas CD28 dominates over CD86, and, finally, the inhibitory PD-L1 dominates over the activating CD86 in cSCC as compared to BCC. This evidence concerns the gene CD274 and skin basal cell carcinoma.